SORAFENIB-ISG

NCT00889057 📎

Regimen

Experimental
Sorafenib 400 mg BID
Control
None

Population

Unresectable relapsed osteosarcoma after standard chemotherapy

Key finding

First positive TKI signal in osteosarcoma. Short duration of benefit — most patients progressed within 6 months — but reproducible activity established angiogenesis inhibition as a viable axis. Opened the door to regorafenib/cabozantinib trials.

Source: PMID 21527590

Timeline

    Guideline citations

    • NCCN BONE (p.31)